Mayo Clinic Announces Collaboration to Spur Biomanufacturing

Get our free mobile app

Rochester, MN (KROC-AM News) - Mayo Clinic is touting a strategic collaboration to bring about "a new era of biomanufacturing."

A news release says the focus will be on therapies derived from human sources for use in medicines, particularly those targeting rare and complex conditions. Those human sources include cells, blood, enzymes, tissues, genes, or genetically engineered cells.

"Mayo is making significant investments in facilities to create the world’s most advanced and innovative ecosystem for the development, manufacture and delivery of biotherapeutics. We are seeking to build a community of innovators to explore ideas, develop new products and create thriving biotherapeutic companies," says Julie Allickson, Ph.D., the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Medicine. "This nexus of entrepreneurs, startups and industry experts will help position Mayo Clinic as an authority in regenerative biotherapeutics." Dr. Allickson is also the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Medicine.

Today's announcement says Mayo Clinic has joined forces with National Resilience Corporation to support the new venture and establish Rochester as "a center for biomanufacturing regenerative technologies." The collaborative effort involving National Resilience and the Mayo Clinic's Center for Regenerative Medicine will be housed in Two Discovery Square in downtown Rochester.

The news release indicates part of the focus of the collaboration will be attracting biotech companies to Rochester to sponsor clinical trials at Mayo Clinic.